Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12617460 | 0.87 | CHRM5 (0.52) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3197414 | 0.82 | TMEM97 (0.48) | CHRM5CHRM4TMEM97SIGMAR1DHFR | |
| SCHEMBL8252006 | 0.82 | SLC6A3 (0.58) | SLC6A2SLC6A3CHRM5CHRM1CHRM2 | |
| SCHEMBL3210652 | 0.82 | PTGDR2 (0.49) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL23166225 | 0.79 | SMN1; SMN2 (0.52) | TMEM97SIGMAR1DHFRPTGDR2NPC1 | |
| SCHEMBL12618060 | 0.77 | PPARA (0.71) | — | |
| SCHEMBL1750649 | 0.77 | CHRM5 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL13547247 | 0.75 | SMN1; SMN2 (0.55) | TMEM97SIGMAR1PTGDR2NPC1RAB9A | |
| SCHEMBL13382410 | 0.72 | TMEM97 (0.46) | TMEM97SIGMAR1DHFRPTGDR2NPC1 | |
| SCHEMBL6415911 | 0.72 | CHRM5 (0.67) | SLC6A2SLC6A3CHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| EP-2064186-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | Glaxo Group Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885CHRM5 146/4885 |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | SLC6A2, NPY5R, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885CHRM5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.